Friday, 1st March at 1.00 PM CET
Since the start of the project, in 2022, WP1 has organized several multi-stakeholder sessions aiming to learn not only the needs and wishes of multiple stakeholder groups, but also the fears, worries and challenges concerning the use of AI in breast cancer treatment response.
The results of the previous sessions were thoroughly analysed by the RadioVal partners and translated into requirements.
On the 1st of March, the RadioVal consortium invites you to provide your feedback and discuss with us how we can all contribute to the common mission of developing trustworthy AI solutions in healthcare. During this final stakeholder session, the RadioVal consortium will show you a first sketch of the tools developed so far and how these tools can address the needs and challenges identified.
In this session, we will bring together representatives from stakeholder groups, including patients, healthcare professionals, AI experts, ethicists, regulators, and policy-makers.
If you are interested and available to join, we kindly ask you to register HERE: https://ec.europa.eu/eusurvey/runner/RadioValSocialInnovation3
The RadioVal project is funded under the Horizon Europe programme and is a major multi-centre, multi-continental and multi-disciplinary project to clinically validate an artificial intelligence solution for the prediction of patient-specific response to neoadjuvant chemotherapy in breast cancer.